Indatuximab ravtansine

Indatuximab ravtansine (in-da-tux-i-mab rav-tan-sine) is a monoclonal antibody designed for the treatment of cancer. It is an antibody-drug conjugate that combines a monoclonal antibody targeting CD138 with a cytotoxic agent, ravtansine.

Etymology

The name "Indatuximab ravtansine" is derived from several components: "inda" refers to the target, CD138, also known as syndecan-1; "tuxi" is a stem used in the names of chimeric monoclonal antibodies; "mab" is a common suffix for monoclonal antibodies; and "ravtansine" is the cytotoxic agent that the antibody is conjugated to.

Mechanism of Action

Indatuximab ravtansine works by binding to CD138, a protein highly expressed on the surface of multiple myeloma cells. Once bound, the antibody-drug conjugate is internalized by the cell, where the cytotoxic agent ravtansine is released. This leads to cell death.

Related Terms

• Monoclonal antibody
• Antibody-drug conjugate
• CD138
• Ravtansine
• Cytotoxic agent
• Multiple myeloma

See Also

• List of monoclonal antibodies
• List of cancer drugs

External links

• Medical encyclopedia article on Indatuximab ravtansine
• Wikipedia's article - Indatuximab ravtansine

This WikiMD dictionary article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski